Eizen Joshua M 4

4 · AN2 Therapeutics, Inc. · Filed Feb 23, 2026

AI-generated summary of this filing

Updated Feb 23, 2026

AN2 (ANTX) COO/CLO Joshua M. Eizen Receives 150,000-Share Award

What Happened

Joshua M. Eizen, AN2 Therapeutics’ Chief Operating Officer and Chief Legal Officer, was granted a total of 150,000 shares on February 20, 2026. The filing shows two award entries: 50,000 shares reported as a grant (common stock/RSUs) and 100,000 reported as a derivative award (RSUs). All were issued at $0.00 (no cash paid).

Key Details

Transaction date: February 20, 2026; Form 4 filed February 23, 2026 (appears timely).
Consideration: $0.00 per share (awarded RSUs, not an open-market purchase).
Vesting highlights:
- 50,000 RSUs: vest 1/4 annually over four years starting January 1, 2026 (F1).
- Existing and additional RSU balances (from filing footnotes) include various tranches totaling prior RSUs with staggered vesting dates from 2024–2026 (F2).
- Options referenced vest monthly over four years from January 1, 2026 (F4).
Other notes: Filing references a prior purchase of 5,000 shares under the 2022 ESPP (F3).
Shares owned after the reported grant are not specified in the summary provided.

Context

These entries are awards of restricted stock units (RSUs), a form of deferred equity compensation. RSUs vest over time and only convert to tradable shares if Eizen remains in service through each vesting date. Awards at $0 are common for executive compensation and do not represent an open-market purchase signal.

Form 4

Period: 2026-02-20

See Remarks

Transactions

Award
Common Stock
[F1][F2][F3]
2026-02-20+50,000→ 207,499 total
Award
Stock Option (right to buy)
[F4]
2026-02-20+100,000→ 100,000 total
Exercise: $1.04Exp: 2036-02-19→ Common Stock (100,000 underlying)

Footnotes (4)

[F1]Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
[F2]Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.
[F3]Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025.
[F4]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Signature

/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen|2026-02-23

1 file